SCHEMBL22004394

SCHEMBL22004394

Cn1c(-c2ccncc2)cc2cc(Cl)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.48
AOC3 Q16853 1/20 0.48
ACLY P53396 1/20 0.46
KMT2A Q03164 2/20 0.45
CYP19A1 P11511 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40
SLC6A2 P23975 1/20 0.40
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
FLT3 P36888 2/20 0.39
AHR P35869 1/20 0.38
CDC7 O00311 1/20 0.38
PKN1 Q16512 1/20 0.38
PKN2 Q16513 1/20 0.38
MEN1 O00255 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HCRTR1 O43613 1/20 0.37
MAPT P10636 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7799883 0.86 KMT2A (0.50) ACLYKMT2ACYP19A1RXFP1AHR
SCHEMBL21812436 0.83 KMT2A (0.47) KMT2ACYP19A1CDC7PKN1PKN2
SCHEMBL31317829 0.83 KMT2A (0.47) KMT2ACYP19A1CDC7PKN1PKN2
SCHEMBL8942357 0.83 KMT2A (0.66) ACLYKMT2ACYP19A1MEN1PHGDH
SCHEMBL22004329 0.83 ACLY (0.49) KCNH2AOC3ACLYKMT2ACYP19A1
SCHEMBL22004125 0.83 ACLY (0.49) KCNH2AOC3ACLYKMT2ACYP19A1
SCHEMBL24115004 0.82 AOC3 (0.53) KCNH2AOC3ACLYKMT2ACYP19A1
SCHEMBL22004395 0.80 KCNH2 (0.45) KCNH2AOC3ACLYCYP19A1SLC6A2
SCHEMBL22004315 0.78 ACLY (0.50) ACLYKMT2ACYP19A1RXFP1AHR
SCHEMBL22021620 0.78 ACLY (0.50) ACLYKMT2ACYP19A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF ACLY, ATP5ME, ATP5MG KCNH2 3425/4885AOC3 2902/4885ACLY 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.